Evidence map›Paper›PMID 26562505›Full record

ArticleJournal of molecular biology2016

A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA.

Lucile Moynié, Anthony G Hope, Kara Finzel, Jason Schmidberger, Stuart M Leckie, Gunter Schneider, Michael D Burkart, Andrew D Smith, David W Gray, James H Naismith

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Phase-Specific Antibiotic Resistance Mechanisms in anbioRxiv : the preprint server for biology · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Lucile MoyniéBiomedical Sciences Research Complex and EaStCHEM, School of Chemistry, University of St. Andrews, North Haugh, St. Andrews, Fife KY16 9ST, United Kingdom. Electronic address: lm108@st-andrews.ac.uk.
Anthony G HopeThe Drug Discovery Unit, James Black Complex, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom. Electronic address: a.g.hope@dundee.ac.uk.
Kara FinzelDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0358, USA. Electronic address: kfinzel@ucsd.edu.
Jason SchmidbergerDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden. Electronic address: jason.schmidberger@gmail.com.
Stuart M LeckieBiomedical Sciences Research Complex and EaStCHEM, School of Chemistry, University of St. Andrews, North Haugh, St. Andrews, Fife KY16 9ST, United Kingdom. Electronic address: leckiestm@gmail.com.
Gunter SchneiderDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden. Electronic address: Gunter.Schneider@ki.se.
Michael D BurkartDepartment of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0358, USA. Electronic address: mburkart@ucsd.edu.
Andrew D SmithBiomedical Sciences Research Complex and EaStCHEM, School of Chemistry, University of St. Andrews, North Haugh, St. Andrews, Fife KY16 9ST, United Kingdom. Electronic address: ads10@st-andrews.ac.uk.
David W GrayThe Drug Discovery Unit, James Black Complex, University of Dundee, Dow Street, Dundee DD1 5EH, United Kingdom. Electronic address: d.w.gray@dundee.ac.uk.
James H NaismithBiomedical Sciences Research Complex and EaStCHEM, School of Chemistry, University of St. Andrews, North Haugh, St. Andrews, Fife KY16 9ST, United Kingdom; State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, China 610065. Electronic address: naismith@st-andrew.ac.uk.
University of St Andrews · GBKarolinska Institutet · SEUniversity of California, San Diego · USUniversity of Dundee · GBSichuan University · CN

Funding

Protein-Protein Interactions in Natural Product BiosynthesisR01GM095970 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURKART, MICHAEL D. · 2012 to 2025
$5.9M
Medical Research Council MC_PC_14099NIGMS NIH HHS R01 GM095970Wellcome Trust 100209
6 · The paper itself

Abstract

Eukaryotes and prokaryotes possess fatty acid synthase (FAS) biosynthetic pathways that comprise iterative chain elongation, reduction, and dehydration reactions. The bacterial FASII pathway differs significantly from human FAS pathways and is a long-standing target for antibiotic development against Gram-negative bacteria due to differences from the human FAS, and several existing antibacterial agents are known to inhibit FASII enzymes. N-Acetylcysteamine (NAC) fatty acid thioesters have been used as mimics of the natural acyl carrier protein pathway intermediates to assay FASII enzymes, and we now report an assay of FabV from Pseudomonas aeruginosa using (E)-2-decenoyl-NAC. In addition, we have converted an existing UV absorbance assay for FabA, the bifunctional dehydration/epimerization enzyme and key target in the FASII pathway, into a high-throughput enzyme coupled fluorescence assay that has been employed to screen a library of diverse small molecules. With this approach, N-(4-chlorobenzyl)-3-(2-furyl)-1H-1,2,4-triazol-5-amine (N42FTA) was found to competitively inhibit (pIC50=5.7±0.2) the processing of 3-hydroxydecanoyl-NAC by P. aeruginosa FabA. N42FTA was shown to be potent in blocking crosslinking of Escherichia coli acyl carrier protein and FabA, a direct mimic of the biological process. The co-complex structure of N42FTA with P. aeruginosa FabA protein rationalises affinity and suggests future design opportunities. Employing NAC fatty acid mimics to develop further high-throughput assays for individual enzymes in the FASII pathway should aid in the discovery of new antimicrobials.

Indexed as

High-Throughput Screening AssaysCrystallography, X-RayCysteamineEnzyme InhibitorsEscherichia coliFatty Acid Synthase, Type IIModels, MolecularProtein ConformationPseudomonas aeruginosa3-hydroxydecanoic acid N-acetylcysteamine thioesterCysteamineEnzyme InhibitorsFatty Acid Synthase, Type IIco-complexcrystal structuredrug discoveryHTSpathogen

Identifiers

PMID26562505
PMCPMC4840175
OpenAlexW2191940366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.